Patients must have evidence of disease progression per RECIST . prior to enrollment or have evidence of cancer-related pain requiring symptom management with narcotic analgesics
Performance Status of -  (unless due to bone pain)
Three or more pain crises per year in the -year period preceding enrollment (required intravenous pain management in the outpatient or inpatient hospital setting). Clinical documentation of pain management in the inpatient or outpatient setting is required.
Has developed chest pain in the past month
Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than  meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity.
Planned palliative procedures for alleviation of bone pain
Participants with uncontrolled or chronic pain, a score greater than  on the standard pain scale, will be excluded unless otherwise approved by the principal investigator or PIs designee
Contraindication to epidural per Pain Service guidelines
Uncontrolled cancer pain. Participants requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy should be treated prior to enrollment.
use of opiate analgesics for prostate cancer pain within  week of treatment start
Symptomatic prostate cancer as determined by cancer-related pain requiring narcotic pain medication or any other clear and unequivocal symptoms related to prostate cancer
Pain symptoms should be stable (of tolerable Grade  or less).
Pain due to metastatic prostate cancer requiring treatment intervention
TSS of ? on the MPN-SAF TSS . or patients with a single symptom score of ? or two symptoms of ?, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats
Prostate cancer pain requiring regularly scheduled narcotics
Patients taking steroids for disease control or pain management
ECOG performance status ? . (Patients with lower performance status based solely on bone pain secondary to multiple myeloma may be eligible following consultation and approval of the medical monitor)
Moderate or severe symptomatic metastatic disease; subjects who meet either of the following criteria must be excluded:\r\n* A requirement for treatment with opioid analgesics for any reason within  days prior to registration\r\n* Average weekly pain score of  or more as reported on the -point Visual Analog Scale (VAS) on the Registration Pain Log
Patients must have severe SCD defined as  or more of the following:\r\n* Clinically significant neurologic event (stroke) or any neurological deficit lasting >  hours\r\n* History of >=  episodes of acute chest syndrome (ACS) in the -year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea)\r\n* History of >=  severe pain crises per year in the -year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea)\r\n* Administration of regular red blood cell (RBC) transfusion therapy, defined as receiving >=  transfusions per year for >=  year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)\r\n* An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >= . m/sec in adult patients
Report worst pain score ?/ at the target treatment site within the past  hours
Significant liver metastasis or disease-related bone pain requiring scheduled narcotics
Must have average worst pain score within specific range on the NPRS from assessment.
Subjects with additional loci of pain above the mid-thoracic level or other pain disorder due to non-cancer etiology.
Asymptomatic or minimally symptomatic patients (do not require narcotics for prostate cancer-related pain).
Participants with uncontrolled tumor-related pain\r\n* Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should be treated prior to enrollment\r\n* Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastases that are not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
Residual side effects from chemotherapy or radiation, which have not gotten better except for nerve pain or tingling or hair loss.
Uncontrolled tumor-related pain\r\n* Subjects requiring pain medication must be on a stable regimen at study entry\r\n* Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should be treated prior to enrollment\r\n* Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
A score of - on Brief Pain Inventory (BPI)-Short Form (SF) question  (worst pain in last  hours) will be considered asymptomatic, and a score of - will be considered mildly symptomatic
Numerical rating pain scale within  week prior to registration; documentation of the patients initial pain score is required; patients taking medication for pain at the time of registration are eligible
Existing chronic bone pain prior to pegfilgrastim usage
Pain that developed or worsened since breast cancer diagnosis and is not due to identifiable traumatic event or fracture
Patient-reported worst pain score between  and  (inclusive) on a - scale (assessed verbally)
Thumbnail abnormalities on either hand (such as due to chemotherapy or trauma, or artificial nails) that are likely to alter pain perception during testing
Patients must have had a visual analog scoring of pain >=  at the planned treated site within  days of registration; pain must be ongoing or require narcotic pain medicine to control
Narcotic pain prescription and usage information must be available and documented
Uncontrolled pain that results in patient's lack of compliance with the imaging procedures
Ileus, abdominal pain, extensive denudation of intestinal mucosa or stage  GI GvHD.
Patients with persistent distinguishable pain associated with up to  tumors of which a maximum of  tumors will be treated: o If patient has pain from additional sites that are not planned for treatment, the pain from the additional sites must be evaluated as being less intense by at least  points on the NRS compared to the site(s) to be treated.
Patients with persistent undistinguishable pain (pain source unidentifiable)
Patients with pain attributable to their prostate cancer
Prostate cancer pain requiring regularly scheduled narcotics
Asymptomatic or minimally symptomatic disease as demonstrated by Eastern Cooperative Oncology Group (ECOG) performance status  or  and no need for opiate pain medications to control pain/symptoms
Solid tumors with tumor-induced pain
Current analgesic therapies have failed, the subject is not a candidate for, OR the subject is not experiencing adequate pain relief from current pain therapies (e.g. radiation, analgesics)
The 'worst pain' in the last  hours must be reported to be  or above on a scale of  (no pain) to  (pain as bad as subject can imagine)
Pain must be from one painful metastatic lesion involving the bone that is amenable to cryoablation with CT (additional less painful metastatic sites may be present)
All subjects must have radiologic or pathologic evidence of ?  skeletal lesions with or without pain at baseline on bone scan or axial imaging or  skeletal lesion and bone pain within  days prior to the registration.
Patients with one-sided, somatic pain due to tumor involvement below the shoulder level (C dermatome)
Patients with refractory cancer pain who are seen by the supportive care or pain medicine teams, and who either () are on appropriate opioid therapy at the time of consultation, or () who undergo an initial consultation and at least  clinical follow-up evaluations by these services
history suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper quadrant pain.
Tumor-related pain increased above baseline for  weeks and not controlled by a stable dose of opiates
Steroids for the treatment of hypersensitivity or transfusion reactions, nausea/vomiting or pain
Use of opiate analgesics for prostate cancer pain within  weeks before enrollment;
a worst pain of at least  at any time during the week preceding the Screening Visit (based on scale of  to , with  representing \pain as bad as you can imagine\).
During the  weeks prior to randomization, at least  of  consecutive days of BPI Worst Pain NRS items and Worst Stiffness NRS items completed correctly.
Willingness and ability to complete the Worst Pain NRS item, Worst Stiffness NRS item, PROMIS Physical Function Scale, and other self-assessment instruments throughout the study.
The patient has pain that is persistent and distinguishably associated with the target sites to be treated; the patients average Brief Pain Inventory (BPI) pain score (- scale) for last  hours at specified location is > 
Patients may have additional non-painful or minimally painful osseous metastases (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least  points on the BPI compared to the site[s] treated)
Use of controlled schedule III controlled substances for cancer-related pain control
Patients have to meet one of the following criteria to be eligible:\r\n* Disease determined unresectable or entailing unacceptably morbid surgery based on  or more of the following characteristics:\r\n** Multifocal disease\r\n** Disease in which there is involvement or inadequate plane from: neurovascular bundle, bone, skin, or viscera\r\n** Large size in relationship to location OR multi-compartment involvement\r\n* Progression by radiographic imaging (% increase in size by RECIST v. within  months of registration)\r\n* Patients with symptomatic disease which meets the following criteria Brief Pain Inventory (BPI) score greater than or equal to  AND one of the following:\r\n** Inability to control pain with NSAIDs and considering addition of narcotics OR\r\n** > % increase in current use of narcotics OR\r\n** Addition of a new opioid narcotic
Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime during the - week period prior to randomization.
Asymptomatic or mildly symptomatic from prostate cancer\r\n* A score of - on Brief Pain Inventory-Short Form (BPI-SF) Question # (worst pain in last  hours) will be considered asymptomatic, and a score of - will be considered mildly symptomatic
Prostate cancer pain requiring regularly scheduled narcotics.
At least  weeks and recovery to grade - from reversible effects or prior surgery (i.e., incisional pain, wound drainage)
Reporting being bothered by vulvovaginal symptoms of estrogen deprivation (i.e., vulvovaginal dryness or discomfort [pain with intercourse or examination])
Patients with a pelvic mass of any size that is causing pain, or other subjective symptoms that are intolerable to the patient
Patients should be asymptomatic for jaundice and ascites prior to day ; pain symptoms should be stable
MRI scan of the target plexiform neurofibroma(s), performed according to study requirements, including axial and coronal short tau inversion recovery (STIR) images within  weeks of enrollment on study; patients with orbital plexiform neurofibromas (PNFs) must have a baseline ophthalmologic evaluation performed prior to study enrollment by an ophthalmologist familiar with the protocol guidelines; patients with pain associated with the target PNF must be able to fill out the Pain Medication Diary with at least one week of documentation prior to study enrollment
Brief Pain Inventory (BPI) worst pain score of ?  (irrespective of medication),
Significant clinical morbidities (aside from the index vertebra(e) and recurrent cancer) that may interfere with data collection that affects pain and functional results,
Pain symptoms should be stable and should not require modifications in analgesic management prior to Cycle  Day .
Subject has chronic low back and leg pain secondary to Failed Back Surgery Syndrome (FBSS)
Subject has an average score of  or higher for average daily overall pain on the Numerical Rating Scale (NRS) based on the  day pain diary
Subject's pain-related medication regimen is stable  weeks prior to the baseline evaluation
Subject agrees not to add or increase pain-related medication throughout the  week randomized evaluation phase of the study (starting at activation)
Clear symptomatic deterioration supported by at least two of the following clinical criteria: ? % worsening in KPS or ?  worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression.
Current analgesic therapies have failed (worst pain of  or above as measured by Brief Pain Inventory [BPI], despite analgesic therapy) OR the subject is experiencing intolerable side effects that preclude analgesic use (resulting in pain of  or above, as measured by BPI)
Radiation while on study is not allowed EXCEPT to a localized region for pain control
Pain scale score >= 
Pain with a focus at the involved vertebral body that is not adequately controlled by medical management
Pain not localized to the region of metastatic disease; this may include:\r\n* Diffuse non-focal back pain\r\n* Radiculopathy
VAS Pain Score > mm on mm scale. -Impending Fracture-Specific Inclusion Criteria
Impending or actual fracture at any other location that, in the Investigator's opinion, would preclude ability to assess pain and/or function in the target humerus.
Between  and  sickle cell-related pain crises in the past  months
Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation
Subject is experiencing acute pain typical of vaso-occlusive crisis requiring treatment with parenteral analgesia
Zubrod Performance Status (PS) of </= ; or  if of recent onset (i.e. <  weeks) and if the compromised performance status is related to uncontrolled pain which is expected to come under control by means of improved pain management.
Persistent clinically significant toxicities from prior chemo ? Grd  or Grd  neuropathy without pain
Persistent clinically significant toxicities from prior chemo ? Grd , or Grd  neuropathy without pain.
Significant neuropathy (Grd - or Grd  with pain) at the time of st dose
Significant neuropathy (Grd - or Grd  with pain) at the time of st dose
Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within  weeks of Cycle  Day 
Is receiving opioids on a regular schedule, not just as needed to control pain.
Patients must not be currently taking (or have taken in the past  months) medication for active, chronic conditions, including rheumatoid arthritis, carpal tunnel syndrome, tenosynovitis, systemic lupus erythematosus, gout, fibromyalgia, or severe osteoarthritis involving the hands, wrists, hips, knees, feet or ankles; this includes analgesic medications or medications being taken with the purpose of treating pain or that may have an effect on pain (e.g. anti-depressants for help with pain or neuropathy, corticosteroid shots for arthritis); (Note: patients taking daily low dose aspirin are allowed to participate in this trial)
Patients must have worst pain rated as no worse than  out of  on the following question (i.e., a pain score of , , , or ): In the past week, how much pain have you had on a scale of  to , where  equals no pain and  means the worst pain you can imagine; \ NOTE: this question regarding patients pain should be completed within one week prior to registration; this question may be asked orally prior to consent up to  days prior to registration; the response will be recorded on the registration checklist
Patients who report a baseline pain score > , unrelated to a breast procedure
Having musculoskeletal pain, defined as regional (joints, extremities, back, neck) or more generalized (fibromyalgia or chronic widespread pain)
Having a pain rating of  or greater in worst pain on a - numerical rating scale in the preceding week (patients with a neuropathic component to their pain that involves the extremities or back will be eligible)
Having had pain for at least  months and at least  days with pain in the preceding  days
Have non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) if these are the sole source of pain, but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined as above
Phantom limb pain
Patients with pain or dysesthesia
Patients able to complete pain assessment and quality of life surveys
Patient has uncontrolled cancer pain despite analgesic therapy
PATIENT INCLUSION: Worst pain in the past  weeks greater than or equal to  on the - pain scale
PATIENT EXCLUSION: Current radiation therapy that in the opinion of the investigator is significantly affecting pain
Pain at baseline as measured by a BPI worst pain score average of >= ; the BPI worst pain score average will be based on the worst pain scores completed by the patient in the  consecutive pretreatment days; a minimum of  days of pain scores must be completed by the patient in the  day window in order to calculate the average worst pain score; the investigator will optimize the subjects pain regimen prior to study entry
Patient with NRS (- scale) pain score ?  irrespective of medication
Worst pain NRS still ?  And
Patients with persistent distinguishable pain associated with  site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least  points on the NRS compared to the site to be treated).
Patients with persistent undistinguishable pain (pain source unidentifiable of the targeted lesion)
Moderate to severe CIPN, defined by symptoms such as numbness, tingling, or pain ratings of  or greater on a  NRS scale
Moderate to severe CIPN, defined by symptoms such as numbness, tingling, or pain ratings of  or greater on a - numeric rating scale (NRS)
Patients with previous pain disorders or drug abuse requiring chronic narcotic use
Pain in the abdomen with an average daily pain rating of >=  out of , using the following question from the Brief Pain Inventory (BPI): Please rate your pain by circling the one number that best describes your (abdominal) pain/discomfort on average over the past week (Scale -; = No pain, = Pain as bad as you can imagine)
Under formal pain management contract with a pain management specialist.
At least moderate pain (pain score >= ) at recruitment
Numeric pain rating scale of >=  out of 
Patients with uncontrolled pain related to cancer or cancer treatment; uncontrolled pain will be defined as\r\n* Pain which persists for more than  days and is rated >=  on NPRS\r\n* Use of breakthrough medication more than  times in  hours or being treated with oral morphine equivalent of  mg/d or more
Patients who are willing and able to maintain a daily pain diary
Patient must be on a stable dose of adjuvant pain therapies for one week prior to screening or after - half-lives of adjuvant pain therapies (i.e., glucocorticoids, nonsteroidal antiinflammatory drug [NSAIDs], anticonvulsants, pharmaceutical cannabinoids, tricyclic antidepressants)
Patient has uncontrolled or rapidly escalating background pain
Uncontrolled pain; if patient is on opioids for the treatment of cancer pain, he/she must have had no major dose change (> %) for at least  hours prior to study entry; the dose of morphine equivalent daily should not exceed  mg/day unless approved by the principal investigator (PI); change in opioid dose after study entry is allowed
Significant pain during core biopsy as reported by the patient
Must either be getting her first mammogram or based on prior experience be expecting level ,  or  pain
May not have taken ibuprofen or other pain medication within the last  hours (aspirin [ASA]  mg dose is allowed)
Having a pain intensity rating of >= ; a pain score of  is considered to be moderate pain
Have persistent pain (unrelated to aromatase inhibitors or chemotherapy-induced peripheral neuropathy) for at least  months following treatment for breast cancer
Have pain severity (arithmetic mean of four pain severity items) >=  on Brief Pain Inventory (BPI)
Have worst pain >= to  (- numeric rating scale [NRS]) in the preceding week
Patients with chronic pain syndromes
Have reported pain as a concern as well as psychological distress on a National Comprehensive Cancer Network (NCCN) screener
Pain score of at >=  on a scale of    within a week of enrollment OR pain score <  with >=  mg of morphine (or equivalent) per day
Experiencing ongoing pain and/or stiffness in one or more joints, which started or worsened after initiation of AI therapy
Having a baseline worst pain score over the past week on the Brief Pain InventoryShort Form (BPI-SF) of >=  on a  to  scale
Has developed chest pain in the past month
Moderate-to-severe bone pain (i.e., National Cancer Institutes Common Terminology Criteria for Adverse Events grade - bone pain)
No plans to change pain medication regimen during the course of the study
Patients with pain at rest or with movement measured by numeric rating scale (NRS) > 
Patient must self-report having chronic pain for at least the past  months that has interfered with their daily functioning, as assessed by the Pain Interference Index (must get a mean score of . or higher, or score a  on three or more individual items)
No anticipated major changes in their pain treatment regimen (i.e., new class of pain medication starting or change in the class of pain medication) or enrollment on a new treatment study presumed to impact pain in the near future
Subjects who are participating in any other treatment studies, either medical or behavioral, specifically for pain management
Subjects who began a medical intervention for treatment of their disease that has a possible impact on pain (including mitogen-activated protein kinase kinase [MEK] trials) will not be eligible until after one year on the medical treatment; at that time, eligibility will be discussed with the PI of the medical study to assess the stability of the patients pain and whether further pain-related changes due to the medical treatment are likely
Current pain level >=  and at least one prior score >=  on a - scale as reported in inquiries of electronic health records (EPIC)
Report average pain >=  during the first nine months after surgery on the Breast Cancer Pain Questionnaire
Patients must have the ability to understand visual and verbal pain scales
Distal symmetric pain distribution (both feet, with or without pain in hands)
Pain duration >  months
Patient report of average daily pain intensity >  on - Numerical Rating Scale (NRS) in the past week
Patients who have frank mechanical pain
Taking daily antihistamines for allergies, asthma, or other indications, not including bone pain
Having  clinical pain ratings of >=  gathered as part of their routine clinic visits at least  weeks apart but not more than  months apart
Current or past (<  months) engagement in pain coping skills training protocol for cancer
Evaluation by a pain management physician and confirmation that cancer is the primary etiology of patients pain
Moderate to severe pain, as specified by a baseline pain rating score of  or above on a scale from  (no pain) to  (worst pain imaginable) despite current opioid therapy
Pain management plan (as developed by Interventional Pain Service, patient and primary service) that includes placement of an intrathecal drug delivery system for pain management
Acute coronary syndrome as defined by active chest pain, dynamic electrocardiogram (ECG) changes, troponin greater than .
Report a clinical pain score of >= /
Subjects with mucositis pain refractory to topical management, defined as any self-reported pain score of >=  in the  hours prior to enrollment despite use of topical agents as prescribed
Pain or symptoms of neuropathy or pain of >=  month ( days) duration for which the patient wants intervention
Participants have to relate that tingling or pain was at least a four out of ten problem during the prior week, on a - scale where zero was no problem and ten was the worst possible problem and expected to have tingling or pain of at least / at the time of the first treatment
Subjects report persistent pain in the distribution of the intercostobrachial nerve (ICBN): The residual breast, surgical bed, ipsilateral medial arm, and/or axilla following tissue healing (>  months post-procedure)
Positive response to local anesthetic peripheral nerve block performed under imaging guidance, defined as a >= % change in Visual Analog Scale (VAS) pain intensity
Presence of pain primarily due to chemotherapy induced peripheral neuropathy
No plans to change pain medication regimen during the course of the study.
Patients with pain requiring opioid pain medication; NOTE: over the counter analgesics such as Tylenol or ibuprofen are allowed
Patients scoring greater than  on a  to  scale with regard to sleep troubles or pain
Patients who are on medications for chronic pain
Patients with chronic pain syndrome or requiring/using chronic pain medications
Numerical Rating Pain Scale within  week prior to registration; the patient must have a score on the scale of >=  for at least one of the planned sites for spine radiosurgery; documentation of the patient's initial pain score is required; patients taking medication for pain at the time of registration are eligible
Widespread chronic pain conditions such as fibromyalgia
Any patients prescribed medications for chronic pain and/or neuropathy will be excluded, including patients under treatment of a pain specialist or substance-abuse programs
Patients already enrolled on other studies of systemic pain control agents
Cancer patients with pain that is not curable and who have not responded to opioids at reasonable doses
Able to verbally report pain
Able to indicate pain on a VAS
Arthralgia is moderate to severe joint symptoms-pain, stiffness or achiness-defined as a score of >=  on the Patient Reported Outcomes Measurement Information System (PROMIS) Pain Intensity scale (inquiring about pain, stiffness or achiness); the at its worst score will be used to determine study eligibility
Less than moderate to severe joint symptoms-pain, stiffness or achiness-defined as a score of =<  on the PROMIS Pain Intensity Short Form (SF) a (inquiring pain, stiffness or achiness); the at its worst score will be used to determine study ineligibility
Having  clinical pain rating of >=  gathered as part of routine clinic visits or reports pain of >  at least three days in the last two week upon accrual
>= / arthralgia (in hands, wrist, knees, or hips) while being treated with anastrozole or letrozole which is felt by the patient to be caused by their aromatase inhibitor, as measured by verbally addressing the following question: please rate your pain by picking a number, from  to  ( being none and  being as bad as you can imagine) that best describes your pain from your aromatase inhibitor breast cancer medication on AVERAGE, over the past week\r\n* Note: Patients may, or may not, be taking non-opioid analgesics
Patients must have completed the S Brief Pain Inventory-Short Form (BPI-SF) within  days prior to registration; patients must have an average pain of at least  on the BPI-SF
Able and willing to go at least - hours without narcotic pain medicine, muscle relaxants, sedatives, sleeping pills and alcohol prior to their cognitive testing; they should not have required chronic sedatives, sleeping aids, or narcotic pain medications on a daily basis prior to their diagnosis
Individuals who are not likely to be able to go for  yours without sleeping pills, sedatives, narcotic pain medications, or chlorpromazine (ativan)
Have an average pain intensity score in their feet and/or hands of >=  on a  to  numeric rating scale (NRS) and/or a rating of >=  on a  to  NRSs on any one of the following sensations from the Pain Qualities Assessment Scale (i.e., numb, tender, shooting, sensitive, electrical, tingling radiating, throbbing, unpleasant)
Have pain and or changes in sensation in their feet and/or hands of at least one month duration
Does NOT have changes in sensation and/or pain in their hands or feet
Patients have to relate that tingling or pain was at least a four out of ten problem =<  days prior to registration, on a - scale where zero was no problem and ten was the worst possible problem\r\n* Note: the patient is expected to have tingling or pain of at least / at the time of the first treatment
An average daily pain rating of >=  out of 
Prior celiac plexus block, or other neurolytic pain control treatment
Persistent post-surgical pain at least  months after completion of surgery, chemotherapy, and/or radiation
Background cancer pain that is =< / in the last  hours
Breakthrough cancer pain that is >= / in the last  hours
Stable pain control defined as rescue doses =<  in last  hours
Patients who report persistent or intermittent pain, including aching, tenderness, soreness
Patients who do not report any pain, including aching, tenderness, and soreness
Ability and willingness to communicate the intensity of pain using NRS at the frequency dictated by the protocol
Numeric pain rating scale of >=  out of 
At least  (out of ) patient-reported oral pain related to oral mucositis secondary to RT for which the patient seeks relief, as measured on the Oral Pain Assessment; Note: The pain score must be at least  at the time that the patient starts the first dose of study medication; the patient may be enrolled to the study if s/he, at times, has a pain score of at least , so long as initiation of study treatment begins when the pain score is at least 
Previously experienced paclitaxel induced pain during a current or past paclitaxel treatment that the treating healthcare provider thinks is consistent with the paclitaxel-induced acute pain syndrome; note: formal documentation of prior pain is not required
Patient reports moderate to severe bother for at least one symptom, defined by a Rotterdam Symptom item score >=  on a - scale, for depressive symptoms, anxiety, pain, fatigue, sleep problems, or breathlessness
Patients with no pain and with stable pain (defined as pain under control and on stable doses of opioids for  week) are eligible
Controlled pain and depression symptoms, if present (defined as no change in the morphine equivalent dose of % or change in the dose of antidepressant medication in the past  weeks)
Patients must have completed the S Brief Pain Inventory-Short Form (BPI-SF) within  days prior to registration; patients must have a worst pain score of at least  on the Brief Pain Inventory (item #) that has started or increased since starting AI therapy
Controlled pain and depression symptoms, if present (defined as no change in the morphine equivalent dose of % or change in the dose of antidepressant medication in the past  weeks)
No history of skeletal related events (SRE) within past  months\r\n* Excruciating bone pain requiring radiation therapy (RT)\r\n* Cord compression\r\n* Hypercalcemia (serum calcium > .) \r\n* Pathologic fracture
Patients will also be excluded if they have active bleeding, acute thrombosis, ischemia, hemodynamically unstable, and uncontrolled pain
chronic narcotic pain medication users
Self-report of moderate or higher pain on average during the last week (>  on a - pain intensity numeric scale)
Chronic pain is not cancer-related
Must report at least one of the following: a. How tired did you feel in the past week? at least  on a  point scale (with  = not tired at all and  = extremely tired) b. Did you have trouble sleeping in the past week? with the answer yes c. What was your average pain in the past week? at least  on a  point scale (with  = no pain and  = extremely severe pain)
Inadequately controlled pain even with the use of morphine (visual analog scale [VAS] score > )
Chronic narcotic pain medication user
Unremitting pain that resulted in a return visit to the oncologist. The 'worst pain' in the last  hours must be reported to be  or above on a scale of  (no pain) to  (pain as bad as subject can imagine) despite pharmaceutical pain management
Pain must be from one or two painful metastatic sites in the bone that is amenable to cryoablation with CT or MRI (additional less painful metastatic sites may be present)
Pain from the reported one or two metastatic sites must correlate with an identifiable tumor on CT, MRI, or ultrasound (US) imaging
Stable use of pain medications (no changes within  weeks prior to the cryoablation procedure)
History of chronic pain, long-term narcotic use or being considered for chronic pain consultation postoperatively
Any condition that causes severe pain with exertion
Pain or significant arthritis in the toes of either foot;
Able to walk at least  blocks without chest pain, dyspnea, shortness of breath or fainting
Any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants except platelet inhibitors (NSAIDs as needed for pain are permitted)
Patients who are not awake, not alert, or who cannot express pain or discomfort related to the catheter locks
New onset of chest pain or arrhythmia in the past  months
Chest pain, angina, or heart failure
Pain in supine position
Uncontrolled tumor-related pain: patients requiring narcotic pain medication must be on a stable regimen at registration; symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization; patients should be recovered from the effects of radiation; there is no required minimum recovery period; asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomization
Any implantable medical device that is not MRI compatible (e.g. pacemakers, defibrillators, pain pumps or insulin pumps)
GROUP B (no pain group): Must either have subjective symptoms of painless neuropathy (loss of sensation, worsening balance, strange sensation in fingers and/or toes) or no complaints related to neuropathy
Has pain rated  or higher on a scale of -, with  = no pain at all and  = worst pain imaginable on the day of the first DLss test
Presence of pain that developed or worsened since breast cancer diagnosis (not specifically due to an identifiable trauma [eg fracture or injury]) and has been present for at least  months; average pain must be at least  on a - scale over the past  days
Thumbnail abnormalities on either hand (such as due to chemotherapy or trauma, or artificial nails) that are likely to alter pain perception during testing
Significant symptom burden from presumed diagnosis including large volume ascites, pain requiring narcotic medication, or shortness of breath on exertion
Significant symptom burden from presumed diagnosis including large volume ascites, pain requiring narcotic medication, or shortness of breath on exertion
Poorly-controlled pain with a self-reported pain score of / at the time of enrollment (PCS study)
Patients who are unable to validate their understanding of the pain scale
Nausea, anorexia, abdominal pain or altered bowel habit
Neuropathy with or without pain
Significant neurotoxicity (Grade  with pain or higher) at the time of enrolment